Cover Image
QR Code

APRIL: spring forward also for IgA vasculitis nephritis in children.

The article discusses the use of telitacicept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), in treating refractory childhood IgA vasculitis nephritis (IgAVN). IgAVN is a common pediatric vasculitis that can lead to kidney involvement, and the artic...

Full description

Published in:Pediatric Nephrology Vol. 41; no. 1; pp. 1 - 10
Main Author: Peruzzi, Licia
Format: commentary editorial pictorial tables/charts Journal Article
Published: Springer Nature Jan2026
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=190235783&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 190235783
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        0931041X
        EF1
      jtl: Pediatric Nephrology
      issn: 0931041X
      maglogo: N
    pubinfo:
      dt: Jan2026
      vid: 41
      iid: 1
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        190235783
        185857375
        190235783
        190235783
        10.1007/s00467-025-06839-6
        190235783
      ppf: 1
      ppct: 9
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: APRIL: spring forward also for IgA vasculitis nephritis in children.
      aug:
        au: Peruzzi, Licia
        affil: https://ror.org/048tbm396 Pediatric Nephrology Unit, Regina Margherita Children's Hospital, University of Turin, AOU Città della Salute e della Scienza di Torino, Piazza Polonia 94, 10126, Turin, Italy
      sug:
        subj:
          Purpura, Schoenlein-Henoch Drug Therapy
          Nephritis Drug Therapy
          Recombinant Proteins Therapeutic Use
          Tumor Necrosis Factor
          B Lymphocytes
          Receptors, Cell Surface
          Proteinuria Prevention and Control
          Drug Efficacy
          Patient Safety
          Membrane Proteins
          Child
          Proteinuria Immunology
          Immunosuppressive Agents
          Immunosuppression
          Child: 6-12 years
      ab: The article discusses the use of telitacicept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), in treating refractory childhood IgA vasculitis nephritis (IgAVN). IgAVN is a common pediatric vasculitis that can lead to kidney involvement, and the article highlights the challenges in treating this condition, particularly due to the lack of controlled studies. Recent real-world data indicate that telitacicept may significantly reduce proteinuria and improve kidney function in children with IgAVN, with minimal side effects reported. The findings suggest a potential shift in treatment strategies for IgAVN, emphasizing the need for further research to validate these results and explore the long-term effects of such therapies.
      pubtype: Academic Journal
      doctype:
        commentary
        editorial
        pictorial
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N